Inhibition of platelet function: does it offer a chance of better cancer progression control?

Abstract:

:Thrombocytosis is frequently (10 to 57%) observed in cancer patients. Although the mechanisms underlying thrombocytosis are not yet fully elucidated, tumor-derived factors with thrombopoietin-like activity, growth factors, platelet-derived microparticles, and factors released from bone marrow endothelial cells as well as growth factors secreted by megakaryocytes (acting via an autocrine loop) are claimed to influence this process. The course of cancer is strongly associated with hypercoagulable state, which results from direct influences of tumor cells themselves and various indirect mechanisms. Activated platelets provide procoagulant surface amplifying the coagulation process. It is well documented that proteins of the hemostatic system influence different steps of metastasis, angiogenesis, and proteolytic events. Much less is known about the role of platelets in tumor growth and their possible contribution to prevention of tumor cells from the host immune system. Multidirectional activities of platelets during tumor development and metastatic dissemination create a possibility of introducing antiplatelet agents in anticancer therapy. The spectrum of plausible therapies includes antibodies against glycoprotein IIb-IIIa, direct thrombin inhibitors, protease activated receptor-1 targeted therapy, as well as cyclooxygenase (COX) and lipoxygenase (LOX) inhibitors. However, there is no sufficient information on a specific type of cancer where progression does depend on platelet function. Despite numerous experimental studies conducted, to date none of the new specific antiplatelet agents were tested in clinical trials in a cancer patient population.

journal_name

Semin Thromb Hemost

authors

Sierko E,Wojtukiewicz MZ

doi

10.1055/s-2007-991540

subject

Has Abstract

pub_date

2007-10-01 00:00:00

pages

712-21

issue

7

eissn

0094-6176

issn

1098-9064

journal_volume

33

pub_type

杂志文章,评审
  • The Complications of Vascular Access in Hemodialysis.

    abstract::Complications related to hemodialysis vascular access continue to have a major impact on morbidity and mortality. Vascular access dysfunction is the single most important factor that determines the quality of dialysis treatment. Vascular access stenosis is a common complication that develops in a great majority of pat...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0037-1606180

    authors: Masud A,Costanzo EJ,Zuckerman R,Asif A

    更新日期:2018-02-01 00:00:00

  • Molecular biology and pathophysiology of APC resistance: current insights and clinical implications.

    abstract::APC resistance is often associated with the occurrence of a single point mutation in factor V (factor VLeiden) at a predominant cleavage site for the natural anticoagulant, activated protein C (APC). In this article we will discuss the effects of this mutation (Arg506-->Gln) on the down-regulation of factor Va cofacto...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-996021

    authors: Rosing J,Hemker HC,Tans G

    更新日期:1998-01-01 00:00:00

  • The nontreatment of childhood ITP (or "the art of medicine consists of amusing the patient until nature cures the disease").

    abstract::The management of childhood acute idiopathic thrombocytopenic purpura is controversial, with recent guidelines highlighting the lack of suitable evidence upon which to base management decisions. Three European centers have used an expectant policy and results over the past decade demonstrate that this is safe and conv...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2001-15256

    authors: Bolton-Maggs PH,Dickerhoff R,Vora AJ

    更新日期:2001-06-01 00:00:00

  • New insights into the role of erythrocytes in thrombus formation.

    abstract::The role of erythrocytes in thrombus formation has previously been regarded as passive by their influence on rheology. Erythrocytes are known, due to their abundance and size, to push platelets to the vascular wall (laminar shearing). This results in an increased platelet delivery at the vascular wall enabling platele...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0033-1363470

    authors: Du VX,Huskens D,Maas C,Al Dieri R,de Groot PG,de Laat B

    更新日期:2014-02-01 00:00:00

  • Whole blood platelet aggregometry and platelet function testing.

    abstract::Platelet aggregometry has been the reference method employed to detect, diagnose, and monitor qualitative platelet disorders since the early 1960s. Lumiaggregometry and impedance-based whole blood lumiaggregometry have advantages over light transmittance aggregometry in that they provide for enhanced specimen manageme...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0029-1220325

    authors: McGlasson DL,Fritsma GA

    更新日期:2009-03-01 00:00:00

  • Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.

    abstract::The present study revises the criteria of the Polycythemia Vera Group (PVSG) for the diagnoses of essential thrombocythemia (ET) and polycythemia vera (PV) in view of accumulating data on in vitro cultures of hematopoietic progenitors and by adding histopathology from bone marrow biopsies. The majority of ET patients ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 指南,杂志文章,实务指引

    doi:10.1055/s-2007-996107

    authors: Michiels JJ,Juvonen E

    更新日期:1997-01-01 00:00:00

  • The Role of Abnormal Hemostasis and Fibrinolysis in Morbidity and Mortality of Acute Promyelocytic Leukemia.

    abstract::Despite the improved therapeutic advances in the management of acute promyelocytic leukemia (APL), a significant early mortality during induction, also referred to as early death (ED), remains an obstacle for further improvement in outcome. Hemorrhagic complications are the most common cause of morbidity and mortality...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0039-1693478

    authors: Kwaan HC,Weiss I,Tallman MS

    更新日期:2019-09-01 00:00:00

  • Plasminogen activator inhibitor-1 in aging.

    abstract::Plasminogen activator inhibitor-1 (PAI-1), a principal inhibitor of fibrinolysis, is induced in thrombotic, fibrotic, and cardiovascular diseases, which in turn primarily afflict the older population. This induction of PAI-1 may play an important role in the pathology of these diseases as PAI-1 can regulate the dissol...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0034-1384635

    authors: Yamamoto K,Takeshita K,Saito H

    更新日期:2014-09-01 00:00:00

  • Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.

    abstract::In order to assess inhibitor development in previously untreated patients (PUPs) with severe (factor VIII [FVIII]<1%) and moderate (FVIII 1 to 5%) hemophilia A, a prospective study was initiated in 1976. During the 23-year study period, 72 hemophiliacs were frequently exposed prophylactically or on demand to plasma-de...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2002-32664

    authors: Kreuz W,Ettingshausen CE,Zyschka A,Oldenburg J,Saguer IM,Ehrenforth S,Klingebiel T

    更新日期:2002-06-01 00:00:00

  • Impact of automation on the quantitation of low molecular weight markers of hemostatic defects.

    abstract::Through in depth studies, the biochemical pathways of hemostasis-related systems have been elucidated in terms of well-defined molecular mechanisms. The interrelationships of coagulation, fibrinolytic, kallikrein-kinin, platelets, prostaglandins, blood vessel, and complement systems are now well understood. Methods ar...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:

    authors: Fareed J,Walenga JM,Bick RL,Bermes EJ Jr,Messmore HL Jr

    更新日期:1983-10-01 00:00:00

  • Coacute heparin: a new simple monotest for monitoring heparin treatment.

    abstract::Anti-factor Xa methods have been generally accepted for the monitoring of heparin treatment mainly due to their sensitivity to LMWH and excellent performance on automated equipment. When such equipment is not available, as in small laboratories or on the night shift, there is a need for a simple manual method. In the ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:

    authors: Friberger P,Krig E,Eriksson-Skoog L,Svensson S,Isacson C

    更新日期:1993-01-01 00:00:00

  • Shear-induced pathway of platelet function in cardiac surgery.

    abstract::The contribution of platelet dysfunction to the impaired hemostasis after cardiac surgery remains to be established, because there is no sensitive method to assess platelet function. Measurement of the shear-induced pathway of platelet function, an important mechanism in inducing hemostasis, became possible by a novel...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0032-1313605

    authors: Tabuchi N,Tigchelaar I,van Oeveren W

    更新日期:1995-01-01 00:00:00

  • Factor XII in Hemostasis and Thrombosis: Active Player or (Innocent) Bystander?

    abstract::Coagulation factor XII (FXII), formerly known as Hageman factor, is a plasma glycoprotein which exerts a kaleidoscope of biological functions, including the initiation of the intrinsic pathway of blood coagulation, the activation of the kallikrein-kinin system, and the generation of bradykinin and angiotensin. The lar...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0036-1571338

    authors: Danese E,Montagnana M,Lippi G

    更新日期:2016-09-01 00:00:00

  • New developments in lung endothelial heterogeneity: Von Willebrand factor, P-selectin, and the Weibel-Palade body.

    abstract::Quiescent pulmonary endothelium establishes an antithrombotic, anti-inflammatory surface that promotes blood flow. However, the endothelium rapidly responds to injury and inflammation by promoting thrombosis and enabling the directed transmigration of inflammatory cells, such as neutrophils, into the alveolar airspace...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0030-1253452

    authors: Ochoa CD,Wu S,Stevens T

    更新日期:2010-04-01 00:00:00

  • Stimulation of cell surface plasminogen activation by heparin and related polyionic substances.

    abstract::The functional operation of the cell surface pro-u-PA and plasminogen activating system has previously been shown to depend on the assembly of u-PA receptors, plasminogen binding sites, and their respective ligands at the focal adhesions of cell extensions. We now show that additional factors operate that affect the p...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-1002610

    authors: Stephens RW,Pöllänen J,Tapiovaara H,Woodrow G,Vaheri A

    更新日期:1991-07-01 00:00:00

  • NETosis: a new factor in tumor progression and cancer-associated thrombosis.

    abstract::Neutrophils have long been known as innate immune cells that phagocytose and kill pathogens and mount inflammatory responses protecting the host from infection. In the past decades, new aspects of neutrophils have emerged unmasking their importance not only in inflammation but also in many pathological conditions incl...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0034-1370765

    authors: Demers M,Wagner DD

    更新日期:2014-04-01 00:00:00

  • Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors.

    abstract::Approximately 5 to 7% of patients with hemophilia A have inhibitory antibodies to factor (F) VIII, which increases to approximately 13% in patients with severe disease. The strongest determinant of the risk of inhibitor development identified is the type of mutation in the FVIII gene that gives rise to the disease. Ho...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2006-946909

    authors: Lee CA,Lillicrap D,Astermark J

    更新日期:2006-06-01 00:00:00

  • Problems and solutions in laboratory testing for hemophilia.

    abstract::A diagnosis of hemophilia A or hemophilia B begins with clinical assessment of the patient and is facilitated by laboratory testing. The influence of the latter on a diagnosis of hemophilia A or hemophilia B is clear-a diagnosis cannot be made without laboratory confirmation of a deficiency of factor FVIII (FVIII) or ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0033-1356573

    authors: Favaloro EJ,Meijer P,Jennings I,Sioufi J,Bonar RA,Kitchen DP,Kershaw G,Lippi G

    更新日期:2013-10-01 00:00:00

  • Monitoring Antiplatelet Therapy.

    abstract::The increasing use of antiplatelet therapy, particularly aspirin and oral P2Y12 inhibitors, in the prevention and management of arterial thrombosis, has stimulated extensive pharmacodynamic studies and research into tailored antiplatelet regimens. Many different methodologies have been studied for monitoring antiplate...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0036-1597298

    authors: Orme R,Judge HM,Storey RF

    更新日期:2017-04-01 00:00:00

  • Description of an in vitro platelet function analyzer--PFA-100.

    abstract::A new in vitro system for the detection of platelet dysfunction, PFA-100, has been developed. It provides a quantitative measure of platelet function in anticoagulated whole blood. The system comprises a microprocessor-controlled instrument and a disposable test cartridge containing a biologically active membrane. The...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0032-1313612

    authors: Kundu SK,Heilmann EJ,Sio R,Garcia C,Davidson RM,Ostgaard RA

    更新日期:1995-01-01 00:00:00

  • Thrombotic microangiopathy in transplantation and malignancy.

    abstract::Thrombotic microangiopathy (TMA) after hematopoietic stem-cell transplantation (HSCT) or solid-organ transplantation is a serious complication that may be associated with diverse clinical conditions. The reported incidence varies widely, in part due to different diagnostic criteria. Currently, the diagnosis is based m...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2005-925475

    authors: Qu L,Kiss JE

    更新日期:2005-12-01 00:00:00

  • Perturbation of protease inhibitors and substrates in inflammatory arthritis.

    abstract::Defective systemic fibrinolysis and articular persistence of fibrinlike material are well recognized in RA. Perturbation of the major plasma protease inhibitors, A1AT, A2MG, and AT III, was explored in RA, psoriatic arthritis, and Reiter's syndrome. Experimental evidence is presented and assessed with respect to the p...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-1004400

    authors: Rothschild BM,Thompson LD,Pifer DD,Chesney CM

    更新日期:1985-10-01 00:00:00

  • Role of plasminogen activator inhibitor-1 in senescence and aging.

    abstract::The average age of the US population continues to increase. Age is the most important determinant of disease and disability in humans, but the fundamental mechanisms of aging remain largely unknown. Many age-related diseases are associated with an impaired fibrinolytic system. Elevated plasminogen activator inhibitor-...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0034-1387883

    authors: Eren M,Boe AE,Klyachko EA,Vaughan DE

    更新日期:2014-09-01 00:00:00

  • Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Microangiopathy in Pregnancy.

    abstract::Thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome (aHUS) are thrombotic microangiopathies (TMAs) that can present in pregnancy. The presentation can be with typical microangiopathic features and thrombocytopenia, but there is also a significant risk of in-utero fetal loss. TTP presents m...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0036-1587683

    authors: Scully M

    更新日期:2016-10-01 00:00:00

  • Hyperhomocysteinemia and thrombosis.

    abstract::Homocysteine has been identified as an independent risk factor for atherosclerotic and thrombotic disease. Both arterial (cerebrovascular, carotid, coronary, and peripheral arterial) and veno-occlusive disease, jointly termed vascular occlusive disease (VOD) in this review, have been associated with hyperhomocysteinem...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-994932

    authors: Guba SC,Fonseca V,Fink LM

    更新日期:1999-01-01 00:00:00

  • A consensus approach to the formulation of guidelines for laboratory testing and reporting of antiphospholipid antibody assays.

    abstract::Despite numerous past and ongoing efforts, there remains significant variation in results from assays for the major antiphospholipid antibodies (aPL), namely anticardiolipin (aCL), anti-beta2 glycoprotein I (anti-beta2GPI), and lupus anticoagulant (LA). There is therefore a need to produce comprehensive guidelines on ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0028-1085479

    authors: Wong RC,Favaloro EJ

    更新日期:2008-06-01 00:00:00

  • Recent Advances in the Molecular Imaging of Atherosclerosis.

    abstract::Atherosclerosis is the major underlying cause of cardiovascular diseases, the prevalence of which is continuously increasing, thus currently standing as the leading global cause of death. This pathology gradually develops over the course of 50 or more years throughout the life of an individual under the influence of a...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0039-1701019

    authors: Larivière M,Bonnet S,Lorenzato C,Laroche-Traineau J,Ottonès F,Jacobin-Valat MJ,Clofent-Sanchez G

    更新日期:2020-07-01 00:00:00

  • The Clinical Relevance of Noncriteria Antiphospholipid Antibodies.

    abstract::While lupus anticoagulant (LA), anticardiolipin antibodies (aCL), anti-β2 glycoprotein I (anti-β2GPI) antibodies represent the best available and the most widely used tests in the investigation for antiphospholipid syndrome (APS), evidence gathered in recent years indicates that other antiphospholipid antibodies (aPL)...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0037-1601328

    authors: Bertolaccini ML,Sanna G

    更新日期:2018-07-01 00:00:00

  • Acquired defects of fibrinolysis associated with thrombosis.

    abstract::Physiologic regulation of fibrinolysis plays an important role in the control of hypercoagulable states and thrombogenesis. Both the hereditary and acquired conditions leading to fibrinolytic deficit result in thrombotic complications leading to arterial and venous occlusive disorders. Several changes in physiologic s...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-994940

    authors: Fareed J,Hoppensteadt DA,Jeske WP,Ahmad S,Bick RL

    更新日期:1999-01-01 00:00:00

  • Pharmacokinetic profile of 14C-labeled clopidogrel.

    abstract::In order to obtain a global assessment of circulating clopidogrel-related products and of the excretion of the drug, the pharmacokinetic behavior and the excretion balance of 14C radioactivity following the administration of a single dose of 75 mg of 14C-labeled clopidogrel were compared in 6 clopidogrel-free healthy ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 临床试验,杂志文章

    doi:

    authors: Lins R,Broekhuysen J,Necciari J,Deroubaix X

    更新日期:1999-01-01 00:00:00